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Abstract
Background: High dietary intake of selenium or soybean isoflavones reduces prostate cancer risk.
These components each affect androgen-regulated gene expression. The objective of this work was
to determine the combined effects of selenium and isoflavones on androgen-regulated gene
expression in rat prostate.
Methods: Male Noble rats were exposed from conception until 200 days of age to diets containing
an adequate (0.33-0.45 mg/kg diet) or high (3.33-3.45 mg/kg) concentration of selenium as Se-
methylselenocysteine and a low (10 mg/kg) or high (600 mg/kg) level of isoflavones in a 2 × 2
factorial design. Gene expression in the dorsolateral prostate was determined for the androgen
receptor, for androgen-regulated genes, and for Akr1c9, whose product catalyzes the reduction of
dihydrotestosterone to 5alpha-androstane-3alpha, 17beta-diol. Activity of hepatic glutathione
peroxidise 1 and of prostatic 5alpha reductase were also assayed.
Results: There were no differences due to diet in activity of liver glutathione peroxidase activity.
Total activity of 5alpha reductase in prostate was significantly lower (p = 0.007) in rats fed high
selenium/high isoflavones than in rats consuming adequate selenium/low isoflavones. High selenium
intake reduced expression of the androgen receptor, Dhcr24 (24-dehydrocholesterol reductase),
and Abcc4 (ATP-binding cassette sub-family C member 4). High isoflavone intake decreased
expression of Facl3 (fatty acid CoA ligase 3), Gucy1a3 (guanylate cyclase alpha 3), and Akr1c9. For
Abcc4 the combination of high selenium/high isoflavones had a greater inhibitory effect than either
treatment alone. The effects of selenium on gene expression were always in the direction of
chemoprevention
Conclusion: These results suggest that combined intake of high selenium and high isoflavones may
achieve a greater chemopreventive effect than either compound supplemented individually.
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Background
Prostate cancer is the most frequently diagnosed cancer in
American men and the second leading cause of all cancer
deaths in men. The American Cancer Society estimates
that there will be about 186,320 new cases of prostate can-
cer in the United States in 2008. About 28,660 men will
die of this disease [1]. Because of its high occurrence and
long latency period, prostate cancer is an ideal candidate
for chemoprevention by dietary means. The Nutritional
Prevention of Cancer Trial showed a significant reduction
in prostate cancer incidence in men receiving a daily sup-
plement of 200 μg selenium (Se) as selenized yeast [2,3].
Chan et al. [4], in their review of diet in the development
and progression of prostate cancer, found the evidence
more convincing for a protective effect of Se than for any
other dietary component. The recently released report of
the World Cancer Research Fund/American Institute for
Cancer Research [5] summarized the available human
data by stating "The evidence from cohort and case-con-
trol studies is consistent, with a dose-response relation-
ship. There is evidence for plausible mechanisms. Foods
containing selenium probably protect against prostate
cancer."
Many possible molecular targets for Se have been identi-
fied [6-9] to account for its chemoprotective effects.
Recent work has focused on the role in chemoprevention
of selenoproteins [10], low molecular weight Se metabo-
lites [11], and reactive oxygen species produced in Se met-
abolic pathways [12]. As a redox agent, Se can alter the
conformation and activity of cellular proteins [13]. The
redox regulation of transcription factors by Se has the
potential to affect expression of multiple genes [14-17],
and therefore the potential to affect risk for prostate can-
cer by multiple mechanisms simultaneously. These mech-
anisms include alteration of various aspects of steroid
hormone metabolism [17,18].
Prostate cancer rates are low in Asian countries where the
diet contains high levels of soy products [19] but high in
countries characterized by consumption of a Western diet
which is traditionally low in soy products [5,20-26].
Estrogenic isoflavones in soy are thought by many to
account for this protective effect [27-31]. The protective
effect of Se has been shown in populations consuming
typical Western, low-soy diets. The purpose of this study
was to determine whether Se and isoflavones may interact
to reduce prostate cancer risk beyond that achieved by
either dietary component alone.
Our working hypothesis is supported by the documented
chemopreventive effects of Se that are due in part to its
effects on androgen metabolism, androgen receptor (AR)
expression and AR-regulated gene expression in the pros-
tate. Androgens (e.g. testosterone) promote prostate can-
cer. Androgen ablation has traditionally been an
important treatment strategy for prostate cancer. The anti-
androgenic effects of Se are similar in many cases to those
reported for isoflavones. The molecular mechanisms by
which these dietary components exert their individual
effects are the targets of current investigation, but little
attention has focused on the potential chemopreventive
efficacy of a supplemental combination of these two die-
tary components.
Methods
Animals and diets
All procedures related to animal care and use were
approved by the Institutional Animal Care and Use Com-
mittee of Brigham Young University. Male and female
Noble rats were purchased from Charles River Laborato-
ries (Wilmington, MA) at thirty-five to forty-two days of
age for use as breeders. This rodent strain has a low spon-
taneous incidence of grossly recognizable adenocarcino-
mas of the dorsal lobe of the prostate [32] but has been
used in numerous studies of hormonally-induced pros-
tate cancer [33] and has shown to be prone to steroid hor-
mone reproductive tumors [34]. Four males and eight
females were assigned to each dietary treatment. The two
basal diets used were the Rodent Phytoestrogen Reduced I
formulation of Zeigler Bros. (Zeigler Bros. Inc., Gardners,
PA) which provides approximately 10 mg isoflavones/kg
diet [35] and 0.45 mg Se/kg, and the Harlan-Teklad 8406
diet (Harlan-Teklad, Madison, WI) which provides
roughly 600 mg isoflavones/kg and 0.33 mg Se/kg. The
detailed composition of these two diets, as previously
reported [36], is shown in Table 1. For 36 of the 43 nutri-
ents listed, the difference in concentration is less than
50%, and for only one nutrient (Vitamin D) is the differ-
ence more than 2-fold. All nutrients were provided in
both diets at levels that met or exceeded the minimum
recommendations of the American Institute of Nutrition
[37]. These two diets were fed with or without a supple-
ment of 3 mg Se/kg diet as Se-methylselenocysteine, a nat-
urally occurring food form of this mineral. The Se-
methylselenocysteine used was a generous gift of Kelatron
Corporation (Kelatron Corporation, Ogden, UT) and was
incorporated into the diets by the manufacturers during
formulation. For this chemical form of Se, the maximum
tolerable dose, defined as "the dose that produced the first
indication of a significant suppression in body weight",
was previously reported to be 5.0 ppm [38]. The Se con-
tent of the high Se diets (3.33–3.45 ppm) used in this
study was less than 70% of that value.
These diets provided Se and isoflavones in food forms and
combinations naturally occurring in foodstuffs, rather
than as semipurified diets with supplements of a single
isoflavone and/or Se compound. The use of these diets,
tested in pups whose exposure to the diets was begun atReproductive Biology and Endocrinology 2008, 6:57 http://www.rbej.com/content/6/1/57
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Table 1: Treatment diets
Unit Harlan-Teklad 8604 Zeigler Bros. Phyto. Reduced I
Nutrient Composition
Protein % 24.48 23.62
Fat % 4.40 5.63
Fiber % 3.69 2.38
Ash % 7.84 6.40
Linoleic Acid % 1.87 2.28
Amino Acids
Arginine % 1.53 1.11
Methionine % 0.42 0.58
Cystine % 0.37 0.27
Histidine % 0.58 0.58
Isoleucine % 1.24 1.17
Leucine % 2.04 2.14
Lysine % 1.46 1.41
Phenylalanine+tyrosine % 1.84 2.05
Threonine % 0.94 0.93
Tryptophan % 0.29 0.25
Valine % 1.26 1.35
Minerals
Calcium % 1.36 1.10
Phosphorus % 1.01 0.92
Sodium % 0.29 0.31
Chlorine % 0.49 0.43
Potassium % 1.04 0.55
Magnesium % 0.28 0.17
Iron mg/kg 352.14 354.26
Manganese mg/kg 105.39 99.93
Zinc mg/kg 82.87 61.69
Copper mg/kg 24.42 12.69
Iodine mg/kg 2.46 1.98
Cobalt mg/kg 0.71 0.57
Selenium mg/kg 0.33 0.45
Vitamins
Vitamin A IU/g 12.90 6.59
Vitamin D3 IU/g 2.40 7.13
Vitamin E IU/g 90.18 51.25
Choline mg/g 2.53 1.63
Niacin mg/kg 63.42 69.47
Pantothenic acid mg/kg 21.03 30.67
Pyridoxine (vitamin B6) mg/kg 12.95 9.46
Riboflavin (vitamin B2) mg/kg 7.85 6.66
Thiamine (vitamin B1) mg/kg 27.95 16.35
Menadione (vitamin K3) mg/kg 4.11 3.15
Folic acid mg/kg 2.72 3.15
Biotin mg/kg 0.39 0.29
Vitamin B12 mg/kg 51.20 47.92
Vitamin C mg/kg 0.00 0.00
Ingredient list (first four) for the Harlan-Teklad 8604 diet: soybean meal, wheat middlings, flaked corn, ground corn Ingredient list (first four) for the 
Zeigler Bros. Phytoestrogen Reduced Diet I: corn, wheat, fish meal, wheat middlingsReproductive Biology and Endocrinology 2008, 6:57 http://www.rbej.com/content/6/1/57
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conception, was intended to imitate dietary conditions in
Asian countries where prostate cancer rates are very low.
While there were minor differences between basal diets in
vitamin and mineral contents, the difference in isoflavone
content was 60-fold. Likewise, the Se-supplemented diets
provided a concentration of Se that was roughly 8–10 fold
higher than the unsupplemented basal diets. Thus, it is
highly likely that differences between diets in gene expres-
sion and other parameters were the result of differences in
Se and isoflavone dietary concentrations, rather than min-
imal differences between diets in other nutrients.
Breeders consumed their respective diets for 30 days prior
to mating. This ensured that pups used as subjects in this
study would be exposed to their respective dietary treat-
ments from conception. Eight offspring in each dietary
group were weighed and sacrificed at 200 days of age.
Blood was collected and dorsolateral prostate lobes and
liver were dissected and weighed, then frozen in liquid
nitrogen and stored at -80°C until analyzed. Many previ-
ous studies looking at androgen metabolism in the rodent
have focused on the ventral prostate, or have not specified
which lobes were examined. Much less attention has been
given to the dorsolateral prostate lobes. However, the
rodent ventral prostate has no clear homologous counter-
part in the human prostate. The rodent dorsolateral pros-
tate is the only prostate lobe comparable to the peripheral
zone of the human prostate, from which most human
tumors develop [39].
Nutritional status assessment – serum analysis, enzyme 
activity
Analysis of serum isoflavone content was performed as
described previously [40]. Briefly, phytoestrogen concen-
trations were analyzed for each dietary treatment group
via gas chromatography/mass spectrometry (GC/MS).
This was performed by liquid-solid extraction and liquid
gel chromatographic techniques to isolate the phytoestro-
gen fractions using standards (internal controls) to vali-
date the assay.
Due to limiting amounts of prostate tissue, activity of
5alpha-reductase in dorsal prostate lobes was assayed in
just two dietary groups. We chose the two groups most
likely to show a difference due to diet – rats fed the ade-
quate Se/low isoflavone diet, and rats fed the high Se/high
isoflavone diet. Analysis was performed as described in
detail elsewhere [41]. Briefly, sections from dorsal pros-
tate lobes were analyzed by TLC using [3H 1,2,6,7]testo-
sterone as the substrate. Radioactivity was then measured
in the reduced steroids [5alpha-androstane-3β, 17-dione,
5alpha-dihydrotestosterone and 5alpha-androstane-
3alpha, 17 β-diol (3alpha-diol)] and activity rates were
calculated. As a measure of Se status, activity of cellular Se-
dependent glutathione peroxidase 1 (EC 1.11.1.9; GPX1)
was assayed in cytosolic fractions from livers of all ani-
mals in each of the four diet treatments as previously
described [42].
Selection of genes for analysis
To select genes for examination in this study we reviewed
the results of the data mining exercise of Zhang et al. [43].
By microarray analysis, they identified 422 AR-regulated
genes in LNCaP human prostate cancer cells, and over
1000 Se-regulated genes in the same cell line. Comparison
of the two lists revealed 92 genes regulated by both Se and
androgen, of which 37 were reciprocally regulated. These
authors also compared differences found in three inde-
pendently published microarray analyses of gene expres-
sion in human prostate tumors compared to normal
human prostate tissue. Over 1000 genes dysregulated in
prostate cancer appeared in all three reports. Of the 37
genes reciprocally regulated by androgen and Se in LNCaP
cells, 6 were among the genes shown by comparison of
microarray analyses to be dysregulated in human prostate
tumors. Thus, the genes selected for analysis in this study
met three criteria: 1) they are dysregulated in human pros-
tate cancer, 2) they are AR-regulated and 3) the androgen
effect is opposed by Se. These genes included Abcc4 (ATP-
binding cassette sub-family C member 4), Dhcr24 (24-
dehydrocholesterol reductase), Facl3 (fatty acid CoA
ligase 3), Gucy1a3 (guanylate cyclase alpha 3), and
human kallikreins 2 and 3. Kallikreins 2 and 3 have no
homologs in rats and were therefore not examined in this
work. In addition to the four AR- and Se-regulated genes
relevant in prostate cancer, for which homologs exist in
rats, we examined expression of the AR itself and of
Akr1c9 – the gene for the enzyme which catalyzes the
reduction of dihydrotestosterone to its corresponding,
less potent 5alpha-androstane-3alpha, 17beta-diol (com-
monly referred to as 3alpha-diol).
Steady state mRNA analysis
Total RNA was isolated from rat dorsolateral prostates
using TRIzol reagent (Invitrogen, Carlsbad, CA). Concen-
tration and purity of RNA were determined spectrophoto-
metrically, and RNA integrity was verified by gel
electrophoresis. Equal quantities from each of three indi-
vidual total RNA isolations within each dietary group
were combined to form a total RNA pool for that group.
Total RNA pools were reverse transcribed using random
hexamers as primers. First strand cDNA was used as a tem-
plate in quantitative PCR analysis (LightCycler, Roche,
Mannheim, Germany) as we have previously described
[44]. PCR Primers (Table 2) were designed using Accelrys
DS gene 1.5 software (San Diego, CA). Optimum temper-
atures for primer annealing were determined experimen-
tally for each primer pair using a range of annealing
temperatures (RoboCycler, Stratagene, La Jolla, CA) fol-
lowed by gel electrophoresis to confirm amplification of aReproductive Biology and Endocrinology 2008, 6:57 http://www.rbej.com/content/6/1/57
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single band of the expected size. For each gene, at least 3
LightCycler runs were performed. Each run included 3
replicates for each diet. Steady state mRNA levels for 18S
rRNA were also quantified and used for normalization.
Western blots
Proteins were isolated from dorsolateral prostate tissue
from three rats in each dietary group. Equal quantities
from each of three individual protein isolations within
each dietary group were combined to form a protein pool
for that group. Proteins (20 μg) were electrophoresed
through denaturing SDS-PAGE gels (NuPAGE Novex 10%
Bis-Tris gels, Invitrogen, Carlsbad, CA) and blotted to
nitrocellulose membranes (Hybond ECL, GE Healthcare
Life Sciences, Piscataway, NJ) as previously described [45].
Membranes were probed with antibodies to actin, AR,
Facl3 (Acsl3), Abcc4 (Mrp4), (Novus Biologicals, Little-
ton, CO), Dhcr24 (Proteintech Group Inc., Chicago, IL),
and Gucy1a3 (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA). A commercial source for Akr1c9 antibody was
not found. Secondary antibodies were conjugated to infra-
red dyes (LI-COR Biosciences, Lincoln, NE) and detection
was by direct infrared fluorescence (Odyssey Infrared
Imaging System, LI-COR Biosciences, Lincoln, NE).
Statistical analysis
Concentrations of amplified products for each replicate of
each gene were calculated by the LightCycler software. To
correct for possible minor differences in pipetting, initial
cDNA concentrations, etc., the final concentration calcu-
lated by the LightCycler software for each replicate of a
gene of interest in a dietary group was normalized by
dividing by the calculated mean for all 18S rRNA repli-
cates in that dietary group.
For each gene, statistical analysis was performed on the 9–
12 normalized replicates for each dietary treatment using
analysis of variance (ANOVA), followed by Fisher's pair-
wise comparison to determine significance of differences
between dietary groups (Minitab, State College, PA). In
the process, a normalized mean value was calculated for
each dietary group. Finally, to compare relative expression
among the four dietary groups for each gene, the 18S-nor-
malized mean for each of the other dietary groups was
divided by the 18S-normalized mean of the adequate Se/
low isoflavone group. These are the values shown in Fig-
ures 1 and 2.
Analysis of 5alpha-reductase data was done using a two-
sample t-test to compare mean values for the adequate Se/
low isoflavone diet to the high Se/high isoflavone diet
(NCSS, Kaysville, UT). Data for GPX1 activity were also
analyzed using ANOVA, followed by Fisher's pairwise
comparison as described above.
Results
Body weight
There were no statistically significant effects of Se on body
weight. This confirms the previous report [38] that the
level of Se fed in the high Se diets in this study was not
toxic to growing rats.
Isoflavone analysis
As expected, serum isoflavone levels were significantly
higher in rats fed the high isoflavone diets. Serum concen-
trations averaged 1254 ± 141 (mean ± SD) and 1659 ±
197 ng/mL in rats consuming high isoflavone diets, with
and without a 3.0 mg/kg Se supplement, respectively (p <
0.05). In contrast, serum concentrations in rats fed the
low isoflavone diets averaged 22.0 ± 2.3 and 24.6 ± 0.1
ng/mL in animals with and without the Se supplement,
respectively. The total serum isoflavone concentrations in
rats fed 600 mg/kg were similar to those of adults living in
Asia while the levels in rats fed only 10 mg/kg were com-
parable to those in persons consuming typical Western
diets [24,46].
Enzyme activity
There were no significant differences due to diet in the
activity of hepatic GPX1. This was expected since all diets
provided a concentration of Se higher than needed to
maximize activity of this enzyme in rat liver. Mean activi-
ties in the four dietary groups ranged from 453–567 mU/
Table 2: PCR primer sequences
Gene Sequence (5' to 3')
Abcc4
- forward TGCTTCCCAGACTCTGCACAAC
- reverse AAGCAAGTCGTCCATGTGTCCG
Akr1c9
- forward CAAGTGCCTTTGAATGCTGAGCC
- reverse ACACCCACTTCATGCCCAAGAC
AR
- forward AGAAAAAATCCCACATCCTGC
- reverse CATCATTTCAGGAAAGTCCACG
Dhcr24
- forward TGCTGAACTCCATTGGCTGGAC
- reverse TTGTGGGACGATGACTCGATGC
Facl3
- forward TCAGGCCAAGGCAAACTCCATTC
- reverse TGCCAAAGCAAACTGGAGGAGG
Gucy1a3
- forward AAGCTGAAGGCAACCTTGGAGC
- reverse TTTGTCCTTGCCAGAGCTGCTGReproductive Biology and Endocrinology 2008, 6:57 http://www.rbej.com/content/6/1/57
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mg protein, which are comparable to previously pub-
lished values for GPX1 activity in Se-adequate rat liver
[42,47]. Figure 3 shows that rats fed the high Se-high iso-
flavone diet had a lower total 5alpha-reductase activity (p
= 0.001) when compared to rats fed diets low in Se and
isoflavones.
Gene expression
Figures 1 and 2 show genes for whose expression the main
effect of Se (Figure 1) or of isoflavones (Figure 2) was sta-
tistically significant. Above each bar graph depicting
steady state mRNA levels is shown an inset of a Western
blot probed with an antibody to that protein. Results of
densitometric scanning of band intensities are shown
above each inset. As noted above, we were unable to find
a commercial source for an antibody to rat Akr1c9. Strip-
ping each blot and probing with an antibody to actin
showed no significant differences in gel loading.
In agreement with findings in cultured cells, high Se
intake by rats in this study dramatically reduced expres-
sion of the AR in the dorsolateral prostate (Figure 1A).
Somewhat surprisingly, the main effect of isoflavones was
not statistically significant.
The Dhcr24 gene codes for an antiapoptotic protein
which inhibits caspase 3. Rats consuming high Se diets
had significantly lower expression of this gene (p < 0.001)
than animals fed diets without the Se supplement (Figure
1B). There was no significant effect of isoflavones on
Dhcr24 gene expression (p = 0.438).
Abcc4 (also called Mrp4) is a member of the multidrug
resistance protein family. Its down-regulation may
enhance the efficacy of anticancer drugs. The main effect
of high supplemental Se intake in reducing Abcc4 gene
expression was statistically significant (p = 0.025) (Figure
Selenium-regulated gene expression Figure 1
Selenium-regulated gene expression. Relative steady state levels (mean ± SEM) of mRNA in the dorsolateral prostates of 
rats fed diets providing 10 or 600 mg/kg isoflavones, and 0 or 3.0 mg/kg supplemental Se for 200 days, were determined by real 
time RT-PCR of total RNA. Analysis of variance was used to determine significance of the main effects of isoflavones and sup-
plemental Se. Fisher's pairwise comparisons within the ANOVA were used to test differences between pairs of dietary groups. 
Bars not sharing a common superscript are significantly different (p < 0.05) by Fisher's pairwise comparisons. Values are 
expressed relative to the expression level of the 0 Se supplement-10 mg/kg isoflavone group. A. Androgen receptor gene 
expression. For the androgen receptor (AR) the main effect of supplemental Se was highly significant (p < 0.001) while the main 
effect of isoflavones was not (p = 0.253). B. Dhcr 24 gene expression. For Dhcr24 the reduction in gene expression due to high 
Se intake was statistically significant (p < 0.001) while the effect of isoflavones was not (p = 0.438). C. Abcc gene expression. 
For Abcc4 (Mrp4) the main effect of high supplemental Se intake in reducing gene expression was statistically significant (p = 
0.025) while the reduction due to high isoflavone intake was not (p = 0.055).
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1C). High isoflavone intake also modestly decreased gene
expression, but that main effect was not statistically signif-
icant (p = 0.055). This was the only gene for which the
combination of high Se and high isoflavones had a more
significant effect than either compound alone, or any
other combination.
High isoflavone intake significantly decreased the expres-
sion of the Gucy1a3 gene (p < 0.001) (Figure 2A). The
product of this gene catalyzes conversion of GTP to the
second messenger cyclic GMP, which regulates the activity
of a variety of protein kinases, phosphodiesterases, and
ion channels. The main effect of Se on Gucy1a3 gene
expression was not significant (p = 0.472).
Facl3 (fatty acid CoA ligase 3, also called acyl CoA syn-
thetase 3, Ascl3) is associated with fatty acid-induced
apoptosis. Ironically, in the cell culture work of Zhang et
al., androgen increased expression of this potentially pro-
tective gene while Se decreased its expression. In this
work, in which rats were rats fed different levels of Se and
isoflavones, high isoflavones significantly down-regu-
lated Facl3 (p = 0.001), but Se had no significant effect (p
= 0.995) (Figure 2B).
Expression of the Akr1c9 gene – the rat homolog of the
human gene whose product reduces dihydrotestosterone
to its 3alpha-diol – is decreased in prostate cancer. Some-
what surprisingly, expression of this gene was also
decreased by high isoflavone intake (Figure 2C). The main
effect of treatment with 3.0 mg/kg Se on expression of
Akr1c9 was not statistically significant, although expres-
sion in the low isoflavone/high Se group was significantly
greater than all other dietary groups.
Isoflavone-regulated gene expression Figure 2
Isoflavone-regulated gene expression. Relative steady state levels (mean ± SEM) of mRNA in the dorsolateral prostates of 
rats fed diets providing 10 or 600 mg/kg isoflavones, and 0 or 3.0 mg/kg supplemental Se for 200 days, were determined by real 
time RT-PCR of total RNA. Analysis of variance was used to determine significance of the main effects of isoflavones and sup-
plemental Se. Fisher's pairwise comparisons within the ANOVA were used to test differences between pairs of dietary groups. 
Bars not sharing a common superscript are significantly different (p < 0.05) by Fisher's pairwise comparisons. Values are 
expressed relative to the expression level of the 0 Se supplement-10 mg/kg isoflavone group. A. Gucy1a3 gene expression. For 
the Gucy1a3 gene the reduction due to high isoflavone intake was highly significant (p < 0.001) while the main effect of Se sup-
plementation was not (p = 0.472). B. Facl3 gene expression. For Facl2 (Acsl3) isoflavones also significantly (p = .001) reduced 
gene expression while supplemental Se had no effect (p = 0.995). C. Akr1c9 gene expression. For rat aldo-keto reductase type 
1 (Akr1c9) a significant (p < 0.001) reduction was seen in rats consuming high isoflavone diets, while the main effect of supple-
mental Se was not significant (p = 0.172).
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Discussion
The AR plays a role in the growth of both healthy prostate
and prostate tumors. Studies of cultured prostate cancer
cells show an inhibitory effect of Se on AR gene expression
[48-51] and various mechanisms have been proposed
[52]. Recently Lee et al. reported that Se injections
decreased AR gene expression in LNCaP xenographs in
nude mice [53]. In this work, we report for the first time a
significant decrease in AR expression in the prostates of
healthy animals fed a nutritionally relevant form of Se.
This confirms findings in the xenograft and in vitro mod-
els and suggests a possible mechanism for the protective
effects of dietary Se against prostate cancer.
Previous studies in cultured cells and animal models have
also shown that high isoflavone treatments reduce AR
gene expression [54-57]. That effect was not seen in this
work. However, most previous studies have employed iso-
lated, individual soy isoflavones (most often genistein) at
widely varying (and sometimes unphysiologic/pharmaco-
logic) levels (50). In some cases, effects of isolated genis-
tein on cultured cancer cells have been shown to be at
variance with the observed chemoprotective effects of soy
product consumption by humans [58-60]. In this work
isoflavones were provided in stock diets formulated from
foodstuffs naturally high or low in phytoestrogens, which
provide isoflavones in their naturally occurring dietary
blend, as is the case for diets consumed by human popu-
lations. It should also be noted that previous animal
experiments have either not specified which lobe of the
prostate was studied or have focused on the ventral lobes,
which have a markedly different gene expression pattern
for AR than the dorsolateral prostate lobes [61]. This study
focused on the dorsolateral lobes of the prostate, which
are the most similar to the human prostate peripheral
zone, in which the majority of prostate tumors develop.
The enzyme 5alpha-reductase uses NADPH to reduce tes-
tosterone to the more potent hormone dihydrotestoster-
one (DHT). El-Bayoumy et al. found no effect on activity
of 5alpha-reductase in healthy men given Se-enriched
yeast [62]. Likewise, Weber et al. found the activity of the
enzyme to be unaffected in rats fed high amounts of iso-
flavones [36]. The observed decrease in 5alpha-reductase
activity in this work suggests that combining Se and isofla-
vones in the diet may produce an effect greater than previ-
ously seen with either treatment alone.
The Dhcr24 gene codes for the enzyme 3beta-hydroxys-
terol-delta24 reductase (alias seladin-1) which catalyzes
Rat dorsolateral prostate 5alpha-reductase activity Figure 3
Rat dorsolateral prostate 5alpha-reductase activity. Activity (mean ± SEM) of 5alpha-reductase was determined in dor-
solateral prostates of rats fed the 0 Se supplement-10 mg/kg phytoestrogen diet, and compared with activity in rats fed the 3.0 
mg/kg Se supplement-600 mg/kg phytoestrogen diet. *The combination of high levels of both dietary components significantly 
reduced enzyme activity (p < .001).
Dietary Treatment
5
a
l
p
h
a
-
R
e
d
u
c
t
a
s
e
 
A
c
t
i
v
i
t
y
(
p
m
o
l
/
h
r
/
m
g
 
p
r
o
t
e
i
n
)
0
1
2
3
4
5
0 Se Supplement
10 mg/kg Isoflavones
3.0 mg/kg Se Supplement
600 mg/kg Isoflavones
*Reproductive Biology and Endocrinology 2008, 6:57 http://www.rbej.com/content/6/1/57
Page 9 of 12
(page number not for citation purposes)
the conversion of desmosterol to cholesterol and regulates
responses to oncogenic and oxidative stimuli [63].
Through its role in cholesterol biosynthesis, Dhcr24 has
been reported to act as an antiapoptotic factor [64] by
functioning in the activation and maintenance of the Akt-
Bad cell survival cascade [65] and the Ras signaling path-
way [66]. Associations between dietary Se, isoflavones,
and Dhcr24 metabolism have not been previously
explored. In this work high dietary Se, but not isoflavones,
decreased the expression of the Dhcr24 gene. This suggests
another mechanism by which Se, through the decreased
expression of this antiapoptotic protein, may be chemo-
preventive.
ATP-binding cassette, sub-family C, member 4 (Abcc4/
Mrp4) is a multiple drug resistance protein that mediates
the efflux out of cells of nucleotide and nucleoside ana-
logues which are an important class of therapeutic agents
[67]. In prostate cancer, Abcc4 expression is up-regulated.
In our study, rats fed high dietary Se experienced a
decrease in Abcc4 gene expression. In addition, the com-
bination of high Se/high isoflavone intake achieved an
effect greater than the use of either compound individu-
ally. This suggests that dietary intervention may enhance
the therapeutic effect of various anti-cancer drugs [50].
Guanylate cyclase 1 alpha 3 (Gucy1a3) catalyzes the con-
version of GTP to the second messenger cyclic guanosine
3',5'-monophosphate (cGMP), which regulates the activ-
ity of protein kinases, phosphodiesterases, and ion chan-
nels [43]. It is consistently overexpressed in prostate
cancer. In LNCaP cells, cGMP activates various forms of
mitogen-activated protein kinases (MAPK) [68], which
leads to phosphorylation of the AR [69] and subsequent
DNA binding. Previous work in LNCaP cells showed that
isoflavones down-regulate MAPK [70]. A decrease in
Gucy1a3 leading to decreases in cGMP and MAPK activity
may correspond to a decrease in AR phosphorylation. Our
finding of a decreased Gucy1a3 expression in rats fed high
isoflavones suggests a possible mechanism for the previ-
ously reported results of isoflavones' effect on MAPK, and
is consistent with a chemopreventive effect due to
decreased AR activation.
Acyl-CoA synthetase long-chain family member 3 (Facl3/
Acsl3) catalyzes the initial reaction of fatty acid metabo-
lism to produce Acyl-CoA and is associated with fatty acid-
induced apoptosis. Interestingly, Facl3 is upregulated by
androgen [51] and vitamin D3 [71] acting through an AR-
mediated pathway in LNCaP cells. In the same cell line Se
was shown to decrease Facl3 expression [43]. This is con-
sistent with Se's established effects in cell culture on AR
expression. In contrast, in rats fed varying combinations
of Se and isoflavones, only isoflavone consumption was
associated with a significant decrease in the expression of
this gene. This is the first report of a relationship between
isoflavone consumption and Facl3 gene expression. Waku
et al. showed that Facl3 inhibits the thyroid receptor [72],
which is a member of the nuclear hormone receptor fam-
ily. The effects of Facl3 on the AR and other members of
the nuclear receptor family remain to be explored.
The rodent enzyme Akr1c9 is a member of the aldo-keto
reductase superfamily. The physiologic function of
Akr1c9 is to catalyze the reversible reduction of dihy-
drotestosterone to androstanediol [alpha-diol] [73]. In
this way, Akr1c9 regulates intracellular hormone concen-
tration and ligand availability for the AR. A key step in AR
activation is ligand binding of DHT. An increase in Akr1c9
mRNA expression would be consistent with chemopre-
vention by decreasing DHT availability for the AR. How-
ever, in rats fed diets containing high levels of isoflavones,
there was an unanticipated decrease in Akr1c9 mRNA lev-
els. One possible explanation is that the Akr1c9 gene is
positively regulated by steroid hormone receptor activa-
tion [74]. There may be a correlation between the
observed decrease in AR mRNA levels in this work and the
decreased expression of Akr1c9, an AR-regulated gene.
Figure 4 summarizes our results and is a proposed model
for the molecular mechanisms by which Se and isofla-
vones may exert their previously demonstrated inhibitory
effects on prostate cancer development and progression.
For those genes whose expression was significantly altered
by high Se intake, the effects of diet were consistent with
cancer chemoprevention. In contrast, in two of the three
cases where high isoflavone intake had a statistically sig-
nificant effect on gene expression, the effect was in the
opposite direction of that associated with protection. It
should be noted that the four genes from the data mining
experiment selected for study in this work were chosen
based on their relevance in prostate cancer and on their
responsiveness to Se and androgen, not isoflavones. The
effects of isoflavones on expression of these genes strongly
suggest that foods containing isoflavones may be chemo-
preventive even though not every effect on expression of
individual genes is in the direction of protection.
Conclusion
In summary, this is the first report of AR down-regulation
by dietary Se in healthy animals. The dietary effects
observed suggest mechanisms for Se's previously demon-
strated chemopreventive properties. In addition, the
observations that a) high Se and high isoflavones each
had significant effects on expression of different genes;
and b) the combination of high Se and high isoflavone
intake significantly reduced Abcc4 gene expression, com-
pared to the other three dietary groups, suggest that a
combination of these two dietary components consumed
at high levels may achieve an even greater chemopreven-Reproductive Biology and Endocrinology 2008, 6:57 http://www.rbej.com/content/6/1/57
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tive effect than high consumption of either compound
alone.
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Proposed model and summary Figure 4
Proposed model and summary. The statistically significant main effects of Se and isoflavones on gene expression are 
shown, as well as the significant combined effect of high Se-high isoflavone intake on 5alpha reductase activity. The model 
shows the role of each gene product in metabolic pathways and the relationship of those pathways to one another. Elucidation 
of effects on gene expression in this study suggests molecular mechanisms for the individual effects of chemopreventive Se and 
isoflavones individually, and the potential for an enhanced protective effect by combining the two dietary treatments.
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